1. Pluvicto, Novartis' first licenced radioligand therapy for
PSMA-positive mCRPC, will be the subject of a subgroup
Analysis
ASCO 2022 Conference
Pluvicto (177Lu-PSMA-617) was the first FDA-approved targeted radioligand therapy (RLT) for eligible
patients with mCRPC in March 2022. Pluvicto (177Lu-PSMA-617) is a combination of a targeting
chemical (ligand) and a therapeutic radioisotope. The FDA granted approval based on the results of the
pivotal Phase III VISION trial, which showed a statistically significant reduction in the risk of death in
patients with pretreated PSMA-positive mCRPC who received Pluvicto plus standard of care; both
alternate primary endpoints of overall survival and radiographic progression-free survival were met.
The business is presently concentrating on the subgroup analysis component of Pluvicto in mCRPC,
which will be presented as an oral presentation at the ASCO 2022 Conference on June 5, 2022. 177Lu-
PNT2002 (PNT2002), another radiopharmaceutical created by Point Biopharma, is a PSMA-targeted
therapy for mCRPC that combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting
radioisotope lutetium-177. The corporation disclosed academic research in order to jump right into a
Phase III clinical trial. They're working on determining whether their treatment is better than the
standard of care in mCRPC patients, with top-line data from the Phase III study expected in Q3 2023.
Abstract Number – 5016
Modra Pharmaceuticals will present Phase II data in patients with mCRPC on oral docetaxel plus
ritonavir (ModraDoc006/r).
2. Modra Pharmaceuticals published positive results from its Phase IIb trial comparing its enhanced oral
taxane treatment, ModraDoc006/r, to the standard-of-care, IV chemotherapy docetaxel, in patients with
mCRPC in February 2022. In addition, a pivotal study for ModraDoc006/r in patients with mCRPC is now
being developed.
The first-line treatment choices for metastatic CRPC are diverse, and decisions are chosen based on the
patient's prior treatments, whether for nmCRPC or mHSPC. Patients who have received escalated ADT
for mHSPC with abiraterone, enzalutamide, or apalutamide, for example, should get a different strategy
for mCRPC; in that first-line context, docetaxel chemotherapy (intravenous) plus an ADT combination is
commonly suggested.
In addition, the trial evaluating ModraDoc006/r given orally to improve mCRPC outcomes is still ongoing.
This highlights the need of providing alternative therapeutic choices in first-line mCRPC therapy, which
can help drive market expansion and provide an alternate treatment option for mCRPC patients.
Abstract Number – 5049
The results of a Phase Ib/II trial of sabizabulin in males with mCRPC who had progressed on an androgen
receptor targeted drug will be presented by Veru Pharma.
Sabizaulbin is being tested in a Phase Ib/II trial in individuals with mCRPC who have progressed on an
androgen receptor targeted drug. Veru Pharma will disclose the results of this Phase Ib/II study's final
analysis. At the ASCO GU Cancers Symposium 2022 in February 2022, Veru presented updated clinical
results from the positive Phase Ib/II study of sabizabulin (VERU-111) in 80 men with mCRPC who had
progressed on at least one new androgen receptor-targeting therapy.
In this updated presentation, sabizabulin therapy was shown to have anticancer action that was both
cytotoxic and cytostatic. The ORR was 20.7 percent for patients having detectable illness at baseline (n =
29). In patients with detectable illness at trial entry, the best clinical response (stable disease or
objective tumour response) was 59 percent (17/29). This Phase Ib/II clinical trial backs up the theory.
Abstract Number – 5078
Bayer plans to present findings from the Phase III ARASENS trial following the approval of the NDA.
In May 2022, the US FDA accepted a supplemental new drug application (sNDA) for darolutamide in
conjunction with docetaxel for mHSPC and awarded it Priority evaluation. The application is being
submitted under the FDA's Oncology Center of Excellence's (OCE) Project Orbis programme, which
provides a framework for the simultaneous filing and examination of cancer treatments by collaborating
international health authorities. After mHSPC receives priority review, it would be fascinating to learn
about the efficacy parameters.
Nubeqa (darolutamide) is previously licenced for non-metastatic prostate cancer and is now being
studied in both CSPC and CRPC patients. Given Nubeqa's recent favourable efficacy results when
combined with Docetaxel and ADT, the business is anticipated to press through with the regulatory
submission.
CONCLUSION
3. In men in the United States, prostate cancer is the second largest cause of cancer-related death.
Previously, most of the focus in the field of advanced prostate cancer was on therapeutic research and
development for patients with CRPC, despite the fact that CSPC patients have a poor prognosis and low
quality of life. However, in recent years, the field of mCSPC has expanded as firms such as Bayer have
moved their focus to mCSPC, which is a less congested market than CRPC. Nubeqa's first segment in
prostate cancer, nmCRPC, obtained FDA approval. Nubeqa will likely face tough competition from
Erleada and Xtandi (in both nmCRPC and mCSPC), with Xtandi's patent scheduled to expire by the end of
the year.
Moving on to the already crowded CRPC market, we await the final results of Veru Pharma's Sabizabulin,
which is slated to present its final Phase Ib/II data. However, we still need to see if Modra Pharma's oral
docetaxel can replace IV docetaxel. Other companies like as Merck Sharp & Dohme
(Keytruda/pembrolizumab), Pfizer (Talazoparib), Janssen (Niraparib), Clovis Oncology (Rubraca), Bristol-
Myers Squibb (Opdivo), Exelixis (Cabozantinib), AstraZeneca (Capivasertib), and Genentech (Tecentriq)
are researching new treatments.
To Get a Detailed analysis of ASCO Conference 2022 Abstracts, Visit: ASCO 2022 Detailed Coverage |
ASCO Conference | ASCO Conference 2022 | ASCO Abstract 2022
Some of the Latest ASCO Abstract 2022 Launched:
Can Breyanzi be a hit CAR-T in second-line treatment after failing in the first-line setting for the
patients with R/R Large B-cell lymphoma (LBCL)?
Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its promise in Multiple
Myeloma during ASCO 2022.
Merus’ Zenocutuzumab, a HER2-HER3 Bispecific Antibody, Successfully Targets NRG1 Fusions in
Lung and Pancreatic Cancer
To Know About Healthcare Research Reports by Delveinsight
Technical Due Diligence Firms
Plaque Modification Devices Market
Chronic smell and flavor loss Market
Facial Lines Market
Metastatic Castration-Resistant Prostate Cancer Market
Sarcopenia Market
Paranasal Sinus Cancer Market
Medical Marijuana Market
Stem Cell Market
Proteus Syndrome Market
4. Inflammatory Pain Market
Shigellosis Market
Asperger Syndrome Market
Trending & Popular Healthcare Research Reports
B Cell Chronic Lymphocytic Leukemia Market
Medical Marijuana Market
Opioid-related Disorders Market
Polycystic Kidney Disease Market
UK Healthcare Outlook Report
Urinary Catheters Market
Coronary Microvascular Dysfunction CMD Market
Sick Sinus Syndrome Market
Oncolytic Virus Cancer Therapy Pipeline
Pelvic Organ Prolapse Market
B-Cell Maturation Antigen Targeted Therapies Market
Tuberculosis Market
Sly Syndrome Market
Membranous Nephropathy Market
Proteus Syndrome Market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions
for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy
Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers &
Acquisitions.
Contact Us
Yash
info@delveinsight.com
